BioCentury
ARTICLE | Clinical News

Tipifarnib: Phase II started

June 27, 2016 7:00 AM UTC

Kura began an open-label, U.S. Phase II trial to evaluate 900 mg oral tipifarnib twice daily on days 1-7 and 15-21 of 28-day cycles in about 58 transfusion-dependent patients with lower-risk MDS. The ...